CAR-T Reality Check! The hype is outrunning the evidence, which now lives in a handy dashboard created and presented by Dr. Mike Putman @EBRheum. There are almost as many studies as there are CAR-T treated patients. Few numbers, limited F/U - Yet everyone is gaga about CAR-T. https://t.co/aCtA8il2fD

🆕 #AutoInflammatory / Periodic Fever Syndromes In Memory of Dr. Dan Kastner🕊️ So grateful Dr. Kastner agreed to review this graphic >1 year ago, providing thoughtful input and suggestions to improve the final version 🙏 New Board Review Series for Rheum OnePagers 📟 #RheumX https://t.co/zx8dX2yHkA

Registry Data Shows Liver Risk With Avacopan A new study may add fuel to the fire already burning around avacopan (Tavneos), approved in 2021 to treat anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), which the FDA wants drugmaker Amgen to pull from https://t.co/nHF6RVpq2Z

Glucocorticoids: Use vs.Toxicity This review article addresses the recognition, prevention and management of GC toxicity in rheumatic patients. Despite guidelines and recommendations that GC be tapered, lowered or discontinued, they continue to be widely used with serious https://t.co/rmjoYJzCLD

Rheum Scholarship (8.21.2026) Dr. Cush reviews the news and journal articles from this past week on RheumNow; talking about lumbar belts, scholarships and misdiagnosis. https://t.co/T6uggKb8n7 https://t.co/HJCMQqghaE

39 studies compared Juvenile systemic sclerosis (jSSc) & adult SSc. 935 jSSc vs 15,451 aSSc pts; jSSc had more diffuse cutaneous dz (70% vs 41%), more overlap myositis (33% vs. 5%), arthritis (33% vs 18%), digital ulcers (51% vs 20%), less renal crisis (0% vs 6%) & lower https://t.co/vflarmwSyv

402 RA pts w. symptomatic Extra-articular manifestations (eg, neuropathy, KCS) had significant impairment in quality of life and work productivity, independent of disease activity. They had lower HAQ (0.92 vs 0.68) & more Absenteeism https://t.co/1FH9gyxoxK https://t.co/faToGXpdSQ

A Tribute to Thomas A. Medsger Jr., MD (1936–2026) The rheumatology and scleroderma communities mourn the loss of Dr. Thomas A. Medsger Jr., who died August 15, 2026, in Pittsburgh, at age 89. https://t.co/GGC3pZVfJp https://t.co/n0ckoeQ3ZX

Misdiagnosis of Still's Disease High fever, strange rashes, scary labs often lead to a consideration of Still's disease (AOSD or systemic JIA). Yet the dramatic onset of a systemic disorder may overlap with another, and possibly rarer, systemic disorder that should not be https://t.co/pSfSahO5Nw

Risk of Venous Thromboembolism in RA RA confers a 50–100% excess risk of venous thromboembolism (VTE) that remains even when remission is achieved. Disease control reduces but does not eliminate thrombotic risk. https://t.co/GXvuucL3ze https://t.co/fTw6UY7eZH

JAK inhibitor Drug Market size (worldwide) was valued at $ 5.51 Billion in 2024 & is estimated to reach $ 19.81 Billion by 2033, exhibiting a Compound Annual Growth Rate of 13.66% from 2026-2033. https://t.co/1Krd1TeKv1 https://t.co/k0hx7iXTvn

e-cigarette use assoc w/ a 1.5-fold incr risk of RA & SLE. All of Us Research prg matched 15,909 e-cig users vs nonusers. 66 new RA or SLE among current e-cig (IR 1.43/1,000PYs) vs nonusers (0.93/1,000PYs; IRR 1.54); applies to past or current smokers https://t.co/xYRezwQFYC https://t.co/pnNANfui4Y

VA study of 4108 RA-ILD (2006-21). PRED use was 65-77%, A& 1st line Rx (MMF, AZA, RTX, CTX) incr after ILD, use was low (1.2-12%). MTX decr (47 to 30%), but LEF, TNFi, ABA incr. Predictors of ILD Rx: FVC, CCP+, ILD Dx after 2012. https://t.co/GT3Vwo11w1 https://t.co/KFDKsjkN0k

20 long-standing PsO pts (freq nai,scalp dz) (b/tsDMARD-naive) Rx w/ OL apremilast 30 bid x 6 mos. Enthesitis (MRI or HR-pQCT) stable, PsAMRIS stable; no new erosions, but PASI (11-->5) & TJC signif improved (3.2-->0.8) https://t.co/UjACvXyvKs https://t.co/xfQGcW0yz7